Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam

European Journal of Pharmacology
K NakamuraY Tanaka

Abstract

Aging-, disease- and medication-related imbalance of central dopaminergic neurons causes functional impairment of cognition and neuropsychological delirium in humans. We attempted to develop a new delirium model using the direct dopamine agonist, apomorphine, and a choice reaction performance task performed by middle-aged rats. The psychological properties of the model were assessed by determining behavioral measures such as choice reaction time, % correct and % omission. Apomorphine (0.03-0.3 mg/kg s.c.) produced a dose-dependent impairment of task performance. The dose of 0.1 mg/kg prolonged choice reaction time, decreased % correct and increased % omission, indicating that rats had attentional deficits and a reduced arousal or vigilance but no motor deficits or reduced food motivation. This psychological and behavioral impairment of performance resembled that of clinically defined delirium. In this model, the cholinomimetic, aniracetam (10 mg/kg p.o.), reversed the performance impairment induced by apomorphine. Its two metabolites, 2-pyrrolidinone (10 and 30 mg/kg p.o.) and N-anisoyl-gamma-aminobutyric acid (GABA, 10 mg/kg p.o.), effectively reversed the performance impairment as the intact drug did. Another pyrrolidinone de...Continue Reading

References

Jan 1, 1990·Journal of General Internal Medicine·J Francis, W N Kapoor
Jan 1, 1989·Annual Review of Neuroscience·R E ZigmondA R Rittenhouse
Jan 1, 1988·Neuropsychologia·P BroksS M Stahl
Jan 1, 1987·Alzheimer Disease and Associated Disorders·J L Cummings, D F Benson
Jan 1, 1985·Annals of the New York Academy of Sciences·E SchwamJ Sepinwall
Jan 1, 1985·Annals of Neurology·H Creasey, S I Rapoport
Jan 1, 1974·Journal of Psychiatric Research·H C Fibiger, A G Phillips
Jan 1, 1972·Psychopharmacologia·S Ahlenius, J Engel
Aug 1, 1994·Brain Research. Brain Research Reviews·T StecklerA Sahgal
Jan 1, 1994·Annual Review of Biophysics and Biomolecular Structure·S Nakanishi, M Masu
Apr 1, 1994·European Journal of Pharmacology·T NabeshimaT Hasegawa
Aug 2, 1994·Proceedings of the National Academy of Sciences of the United States of America·M I Posner
Aug 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·E RůzickaR Jech
Feb 1, 1994·Pharmacology, Biochemistry, and Behavior·N Himori, K Mishima
May 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M AmalricG F Koob
Oct 1, 1990·Reviews in the Neurosciences·T W Robbins, V J Brown

❮ Previous
Next ❯

Citations

Jun 20, 2001·European Journal of Pharmacology·K Nakamura, M Kurasawa
Sep 6, 2000·Pharmacology, Biochemistry, and Behavior·Y TanakaK Nakamura
Mar 29, 2001·Pharmacology, Biochemistry, and Behavior·K Nakamura, M Kurasawa
Mar 20, 2002·Pharmacology, Biochemistry, and Behavior·Yushiro TanakaKazuo Nakamura
Oct 31, 2019·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·J L RicoS Morato
Oct 8, 2009·The Oncologist·Shirley H Bush, Eduardo Bruera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.